The New Wave of Psilocybin Trials for Treatment-Resistant Depression
Phase II results were striking enough to sustain a decade of interest. The larger trials now underway will decide whether the effect holds outside a small, carefully selected room.
By Elena Marchetti · July 21, 2026 · 9 min read
Treatment-resistant depression is defined by failure: two or more adequate trials of antidepressants without meaningful response. For roughly a third of people with major depression, that is the situation. It is against this backdrop — not against a healthy baseline — that psilocybin results should be read.
The most cited Phase II work reported rapid reductions in depression scores after one or two supervised sessions, with effects that persisted for weeks in a subset of participants. The size of the change was unusual. So were the conditions: intensive psychological preparation, two therapists present throughout, and participants who knew, almost without exception, whether they had received the active dose.
What the mechanism story actually says
Psilocin, the active metabolite, is an agonist at the 5-HT2A receptor, which is densely expressed on cortical pyramidal neurons. Animal work suggests this triggers a window of increased structural plasticity — dendritic spine growth measurable within 24 hours. The appealing hypothesis is that the drug opens a period in which entrenched patterns can be revised, and that therapy does the revising.
That is a hypothesis, not a finding. Plasticity in rodent cortex is not the same as durable change in human mood, and the field has not yet separated the pharmacological effect from the effect of two prepared clinicians paying close attention for eight hours.
The honest position is that the signal is real, the explanation is provisional, and the durability is unproven.
Where the evidence goes next
Larger multi-site Phase III programs are running with active comparators and longer follow-up. Two questions matter most: whether response survives at six and twelve months without repeat dosing, and whether the effect shrinks when the therapeutic container is standardized rather than bespoke. Regulatory decisions will turn on those answers, not on the early headlines.
In the meantime, psilocybin remains a controlled substance in most jurisdictions and is not an approved treatment. Ketamine and esketamine are the only rapid-acting options currently available through conventional care.
Sources / Further reading
- Carhart-Harris et al., Trial of Psilocybin versus Escitalopram for Depression, NEJM (2021)
- Goodwin et al., Single-Dose Psilocybin for Treatment-Resistant Depression, NEJM (2022)
- Shao et al., Psilocybin induces rapid and persistent growth of dendritic spines, Neuron (2021)
